BACKGROUND: Chronic obstructive pulmonary disease (COPD) is associated with systemic inflammation and oxidative stress. N(ε) -(carboxymethyl) lysine (CML), an advanced glycation end product (AGE) and the soluble decoy receptor, sRAGE, are exciting new molecules linked to oxidative stress and inflammation. Here the levels of plasma sRAGE and CML were determined and their variation in relation to lung function, external long-term oxygen therapy (LTOT) and plasma levels of inflammatory molecules in COPD evaluated. METHODS: Plasma sRAGE and CML levels were measured by ELISA in 146 patients with stable COPD and 81 healthy subjects, subgrouped from a larger case-control study and matched for age, gender and pack-years smoked. RESULTS: Decreased levels of plasma sRAGE and no significant difference in levels of plasma CML were found in patients with COPD in comparison with controls. In the total group, plasma sRAGE was positively associated with FEV(1) and forced vital capacity and negatively with pack-years smoked. In patients receiving LTOT, levels of plasma sRAGE were lower compared with those without LTOT. Only in controls, a weak correlation was found between plasma sRAGE and CML. sRAGE did not correlate with measured inflammatory markers, whereas CML was negatively correlated with fibrinogen. CONCLUSION: Plasma sRAGE levels are lower in patients with COPD compared with healthy control subjects, and even lower levels in patients receiving LTOT. Because sRAGE correlated with lung function only in the whole group, sRAGE can be considered a marker of COPD, but not of disease severity. A lack of clear association between sRAGE, CML and systemic inflammation is furthermore evident.
BACKGROUND:Chronic obstructive pulmonary disease (COPD) is associated with systemic inflammation and oxidative stress. N(ε) -(carboxymethyl) lysine (CML), an advanced glycation end product (AGE) and the soluble decoy receptor, sRAGE, are exciting new molecules linked to oxidative stress and inflammation. Here the levels of plasma sRAGE and CML were determined and their variation in relation to lung function, external long-term oxygen therapy (LTOT) and plasma levels of inflammatory molecules in COPD evaluated. METHODS: Plasma sRAGE and CML levels were measured by ELISA in 146 patients with stable COPD and 81 healthy subjects, subgrouped from a larger case-control study and matched for age, gender and pack-years smoked. RESULTS: Decreased levels of plasma sRAGE and no significant difference in levels of plasma CML were found in patients with COPD in comparison with controls. In the total group, plasma sRAGE was positively associated with FEV(1) and forced vital capacity and negatively with pack-years smoked. In patients receiving LTOT, levels of plasma sRAGE were lower compared with those without LTOT. Only in controls, a weak correlation was found between plasma sRAGE and CML. sRAGE did not correlate with measured inflammatory markers, whereas CML was negatively correlated with fibrinogen. CONCLUSION: Plasma sRAGE levels are lower in patients with COPD compared with healthy control subjects, and even lower levels in patients receiving LTOT. Because sRAGE correlated with lung function only in the whole group, sRAGE can be considered a marker of COPD, but not of disease severity. A lack of clear association between sRAGE, CML and systemic inflammation is furthermore evident.
Authors: Michelle John; Tricia M McKeever; Maath Al Haddad; Ian P Hall; Ian Sayers; John R Cockcroft; Charlotte E Bolton Journal: Chron Respir Dis Date: 2016-03-10 Impact factor: 2.444
Authors: Poornima Gopal; Niki L Reynaert; Jean L J M Scheijen; Casper G Schalkwijk; Frits M E Franssen; Emiel F M Wouters; Erica P A Rutten Journal: Respir Res Date: 2014-02-25
Authors: Bartosz Sokół; Norbert Wąsik; Roman Jankowski; Marcin Hołysz; Witold Mańko; Robert Juszkat; Tomasz Małkiewicz; Paweł P Jagodziński Journal: Biomed Res Int Date: 2017-05-29 Impact factor: 3.411
Authors: Suzanne Miller; Amanda P Henry; Emily Hodge; Alexander K Kheirallah; Charlotte K Billington; Tracy L Rimington; Sangita K Bhaker; Ma'en Obeidat; Erik Melén; Simon K Merid; Caroline Swan; Catherine Gowland; Carl P Nelson; Ceri E Stewart; Charlotte E Bolton; Iain Kilty; Anders Malarstig; Stuart G Parker; Miriam F Moffatt; Andrew J Wardlaw; Ian P Hall; Ian Sayers Journal: PLoS One Date: 2016-10-18 Impact factor: 3.240
Authors: Susan J M Hoonhorst; Adèle T Lo Tam Loi; Simon D Pouwels; Alen Faiz; Eef D Telenga; Maarten van den Berge; Leo Koenderman; Jan-Willem J Lammers; H Marike Boezen; Antoon J M van Oosterhout; Monique E Lodewijk; Wim Timens; Dirkje S Postma; Nick H T Ten Hacken Journal: Respir Res Date: 2016-04-26